北京若生智能科技有限公司
Drug Database
BE

beclometasone dipropionate (EcoBec / Beclazone / Beclazone)

✓ Approved

Teva Pharmaceutical Industries Ltd. · NR3C1 · 小分子

什么是 beclometasone dipropionate？

beclometasone dipropionate 是一种小分子，由Teva Pharmaceutical Industries Ltd.研发。该药已获批，用于治疗相关适应症，给药途径：Inhaled。

药物档案

商品名EcoBec, Beclazone, Beclazone
公司Teva Pharmaceutical Industries Ltd.
药物类别小分子
分子靶点NR3C1
给药途径Inhaled
状态Approved
来源： ClinicalTrials.gov, Teva Pharmaceutical Industries Ltd.

作用机制

分子靶点

beclometasone dipropionate 作用于 1 个分子靶点：

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

beclometasone dipropionate 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved

相关研究文献

PubMedFrontiers in veterinary science2026-09-10

Synergistic in-vitro activity of Fosinopril alone and in combination with imidocarb dipropionate against Babesia bovis.

Bhowmick Biswajit B, Lacy Paul A PA, Suarez Carlos E CE, Chung Chungwon J CJ

Bovine babesiosis, caused by Babesia bovis is a major cattle disease worldwide, particularly in tropical and subtropical regions. A commonly used drug for the control and treatment of babesiosis is imidocarb dipropionate (ID), which has proved effective against B. bovis. Nevertheless, its toxicity to ruminants and other mammals, along with the persistence of drug residues in meat and milk for several months after treatment, has led to restriction on its use. Furthermore, several reports indicate that complete parasite elimination is not obtained in some cases. Interestingly, the angiotensin-converting enzyme (ACE) inhibitor Fosinopril has been recently found to exhibit potent antibabesial activity against Babesia duncani. In this study, we investigated the in-vitro activity of Fosinopril alone and in fixed-ratio combinations with ID against the B. bovis Texas T2Bo isolate. Quantitative dose-response analyses of the in-vitro activity showed that Fosinopril exhibited measurable activity against the Babesia bovis T2Bo isolate, with an IC50 value of 541.2 nM, whereas ID demonstrated greater potency, with an IC50 value of 124.3 nM. When fixed-ratio combination studies were conducted to evaluate interactions between two drugs, the low-dose regimen Comb-4 (108 nM Fosinopril + 25 nM ID) was the only tested combination that met the predefined ΣFIC criterion for synergy (ΣFIC = 0.40). MDBK cells viability testing showed that ID reduced cell viability at the parasite-relevant concentration tested, whereas Fosinopril and the low-dose combination treatments maintained high MDBK cell viability under the same in-vitro screening conditions. Overall, these proof-of-concept in-vitro findings suggest that Fosinopril has potential as a repurposed therapeutic agent for the treatment of B. bovis-infection in cattle. Low-dose Fosinopril-ID combinations may provide a dose-sparing direction for future pharmacological studies.

PMID 42718422
阅读全文 →
PubMedCureus2026-09-06

Psoriasiform Dermatitis Following JAK Inhibitor Therapy for Hidradenitis Suppurativa and Crohn's Disease.

Caussade-Silvestrini Gerardo S GS, Gerena-Maldonado Cristina P CP, Rodríguez-Rivera Rafael E RE, Alvarado-Ramos Natalia A NA et al.

Upadacitinib, a selective JAK1 inhibitor approved for hidradenitis suppurativa (HS) and Crohn's disease (CD), has been implicated in paradoxical inflammatory reactions; however, upadacitinib-induced psoriasiform dermatitis in patients treated for HS has not been previously described to the best of our knowledge. We report a 55-year-old woman with HS, CD, rheumatoid arthritis, and systemic lupus erythematosus, receiving upadacitinib 30 mg daily, who developed a pruritic erythematous scaly plaque on the lower back without personal or family history of psoriasis. Punch biopsy demonstrated psoriasiform dermatitis with acanthosis, focal hypogranulosis, uniform elongation of rete ridges, spongiosis, parakeratosis, and a superficial perivascular lymphocytic infiltrate. Given upadacitinib's established efficacy for both HS and CD, the drug was continued, and topical augmented betamethasone dipropionate was initiated, achieving adequate control at two-week follow-up. This case inverts the established paradigm in which JAK inhibitors serve as rescue agents for paradoxical reactions triggered by anti-TNF-α biologics. Comparable psoriasiform eruptions have been reported with baricitinib and tofacitinib, primarily in rheumatoid arthritis, a comorbidity present in our patient and an important interpretive caveat. We hypothesize that interferon-gamma (IFN-γ)-mediated STAT1 dysregulation intrinsic to HS pathogenesis may lower the threshold for JAK inhibitor-induced immune imbalance, although this mechanism remains speculative and warrants further investigation. Paradoxically, upadacitinib has also resolved psoriasiform eruptions in HS, underscoring the bidirectional and unpredictable nature of JAK1 inhibitor-mediated immune modulation. Psoriasiform dermatitis may represent a paradoxical cutaneous reaction to upadacitinib in patients with HS, warranting vigilant dermatologic monitoring and further investigation into individual susceptibility factors.

PMID 42699819
阅读全文 →
PubMedVestnik otorinolaringologii2026-09-04

[Topical Therapy of Otitis Externa: Potential Use of Combined Preparations].

Baranov K K KK, Kotova E N EN, Vyazmenov E O EO, Titova E V EV et al.

To assess the potential use of a combined topical preparation in the form of ear drops containing chloramphenicol, clotrimazole, beclomethasone dipropionate, and lidocaine in the treatment of patients with acute otitis externa, based on the clinical presentation and characteristics of the microbiological profile. A retrospective analysis of medical records of 168 patients with acute otitis externa over a 5-year period was performed. The study included children older than 6 years and adult patients. All patients underwent otorhinolaryngological examination, culture-based microbiological testing of discharge from the external auditory canal with species identification, CFU/mL counts and analysis of antimicrobial susceptibility data for clinically significant bacterial isolates according to laboratory reports, as well as local therapy with a combined topical preparation in the form of ear drops containing chloramphenicol, clotrimazole, beclomethasone dipropionate, and lidocaine. In cases where inflammation spread to the skin of the auricle, a combined ointment containing chloramphenicol and methyluracil was additionally used. Treatment efficacy was assessed based on the dynamics of subjective symptoms and objective signs of inflammation; tolerability was evaluated according to the presence of adverse events. Statistical analysis included calculation of mean values and proportions. Positive clinical dynamics were observed with the use of the combined topical ear drop preparation in patients with acute otitis externa: therapy resulted in regression of the main symptoms in 96.4% of patients, including reduction of otalgia, edema, hyperemia of the external auditory canal skin, and pathological discharge. Combined topical therapy with an ear drop preparation demonstrated high efficacy and a favorable safety profile in the treatment of acute otitis externa in children older than 6 years and adult patients, providing positive clinical dynamics in 96.4% of patients.

PMID 42693983
阅读全文 →
PubMedPathogens (Basel, Switzerland)2026-08-27

Treatment Efficacy of Imidocarb Dipropionate in Saanen Goats Experimentally Infected with Babesia aktasi.

Ulucesme Mehmet Can MC, Ozubek Sezayi S, Aktas Munir M

Babesia aktasi is a recently discovered species that is highly prevalent in native goats in Türkiye's Mediterranean region. Although it does not induce clinical disease in local breeds, it causes severe illness in Saanen goats, manifesting with high fever, anemia, hemoglobinuria, and jaundice. Imidocarb dipropionate (IMDP) has been reported to be therapeutically effective against Babesia species. This study aimed to evaluate the therapeutic efficacy of IMDP and its ability to eliminate the parasite in experimentally infected Saanen goats. Twelve goats were assigned to treatment and control groups (n = 5 per group) and infected using fresh blood from two splenectomized donors. All goats developed clinical babesiosis, with parasitemia ranging from 3.8% to 22. Semi-nested PCR specific to B. aktasi was performed for 30 days post-treatment. Following treatment with IMDP (1.2 mg/kg), clinical signs resolved by the third and fourth days, and parasitemia became microscopically undetectable. However, one goat in the treatment group and four goats in the control group died shortly after infection. Hematological parameters (HCT, RBC, HB) decreased during infection but normalized in surviving animals. Notably, B. aktasi DNA remained detectable by PCR up to 30 days after treatment. These findings indicated that IMDP resolved clinical signs and eliminated microscopically detectable parasitemia; however, it may not completely eliminate the parasite at the molecular level in B. aktasi infections. The results of this study provide valuable information for optimizing therapeutic approaches and improving our understanding of treatment responses in new species B. aktasi.

PMID 42654770
阅读全文 →
PubMedVeterinary medicine and science2026-08-27

Clinical Case and Follow-Up of Babesia banethi Infection in a Red Fox.

Carbonara Mariaelisa M, Prioletti Michela M, Camarda Antonio A, Castellana Stefano S et al.

Red foxes play an important role in the circulation of ticks and tick-borne pathogens, including Babesia spp. While for Babesia vulpes many studies are available on its epidemiology in fox populations as well as pathogenicity in dogs, no data are reported for the recently described Babesia banethi infecting red foxes. Here we describe the clinical and parasitological follow-up of a naturally occurring B. banethi infection in a red fox from southern Italy. An adult male fox presented with severe debilitation, weight loss, pale mucous membranes, brown discolouration of urine and sarcoptic mange. Haematological examination revealed regenerative anaemia associated with left-shift neutrophilia and lymphocytosis. Blood smear examination showed intraerythrocytic inclusions morphologically consistent with small piroplasmids, and PCR amplification and sequencing of the 18S rDNA gene confirmed infection with B. banethi. Screening for other vector-borne pathogens scored negative. Treatment with imidocarb dipropionate resulted in temporary clinical and haematological improvement but persistence of PCR positivity and later relapse of parasitaemia and clinical signs. Subsequently, treatment with atovaquone/proguanil combined with azithromycin led to marked clinical recovery and disappearance of parasites at blood smear examination, although PCR positivity persisted for several months. A second therapeutic course resulted in both cytological and molecular negativity. This longitudinal case report provides the first detailed account of the clinical course, therapeutic response and long-term parasitological follow-up of B. banethi infection in a red fox, suggesting that this piroplasm might cause clinically relevant and persistent infection, yet further validation of this hypothesis on a larger number of clinical cases is advocated. Not applicable.

PMID 42656136
阅读全文 →
PubMedItalian journal of dermatology and venereology2026-08-24

Topical treatment of psoriasis with calcipotriol/betamethasone dipropionate cream in real-life clinical practice: expert opinion.

Gisondi Paolo P, Burlando Martina M, Esposito Maria M, Megna Matteo M et al.

The fixed-dose combination of calcipotriol and betamethasone dipropionate (Cal/BDP) is an established topical psoriasis treatment. The cream formulation of Cal/BDP has been found effective and well-tolerated for the treatment of mild-to-moderate disease, with high levels of patient satisfaction. The aim of this consensus document is to guide optimal real-life use of Cal/BDP cream in patients with psoriasis. Eight hospital-based dermatologists, with long-standing experience in psoriasis treatment, developed a consensus document on three topics (therapeutic protocols and schedules; high-impact areas; and treatment adherence) regarding the use of Cal/BDP cream in clinical practice. A modified Delphi process was used to achieve consensus among panel members. Statements with treatment recommendations, based on the experts' opinions and experience, as well as an analysis of relevant published data, were elaborated on and discussed during two meetings occurring two months apart. Full agreement among panel members was obtained after two online Delphi rounds. As seen in clinical trials, Cal/BDP cream monotherapy has proved beneficial in the treatment of mild to moderate plaque psoriasis. However, it can also be used as an adjunct to systemic/biologic drug treatment or as long-term maintenance therapy. Cal/BDP cream also plays an important role in the treatment of psoriasis on high-impact sites (including the scalp, peripheral facial areas, skin folds and palmoplantar areas) with treatment schedules varying according to disease severity and area involved. Due to its vehicle, treatment with Cal/BDP cream is associated with high levels of treatment convenience and patient acceptability, positively impacting adherence. Cal/BDP cream can be used safely and effectively for the treatment of psoriasis in a range of clinical presentations. Its favorable cosmetic characteristics contribute to treatment success by enhancing patient adherence. Studies on the long-term use of Cal/BDP cream as a maintenance therapy are needed.

PMID 42634951
阅读全文 →

注册免费账户还可查看另外 3791 篇文献

免费注册查看全部文献 →

了解更多beclometasone dipropionate